Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 467
- Registration Number
- NCT02833844
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 6000
- Registration Number
- NCT02808403
- Locations
- 🇯🇵
Research Site, Kofu city, Yamanashi Prefecture, Japan
Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 38
- Registration Number
- NCT02797080
- Locations
- 🇺🇸
University of California, Los Angeles Neurology Clinic, Los Angeles, California, United States
🇺🇸University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸University of Florida Clinical Research Center, Gainesville, Florida, United States
Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT02792517
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT02780674
- Locations
- 🇺🇸
Research Site, Duncansville, Pennsylvania, United States
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 15
- Registration Number
- NCT02756845
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Marseille - Hopital de la Timone, Marseille cedex 5, France
🇺🇸AI Dupont Hospital for Children, Wilmington, Delaware, United States
🇫🇷Institut Hematologie et Oncologie Pediatrique, Lyon cedex 08, France
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 424
- Registration Number
- NCT02739984
- Locations
- 🇪🇸
Research Site, Barcelona, Cataluña, Spain
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
- Conditions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 935
- Registration Number
- NCT02732210
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
- Conditions
- Interventions
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 129
- Registration Number
- NCT02729025
- Locations
- 🇳🇱
Research Site, Waalwijk, Netherlands
Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension
- Conditions
- Interventions
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT02641353
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc, Madison, Wisconsin, United States